RonacMamtaniMDMSCE

Assistant Professor, Medicine, Perelman School of Medicine

Dr. Mamtani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
3400 Civic Center Blvd
2 West
Philadelphia, PA 19104
Phone+1 215-615-5858

Fax+1 212-746-6692

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2009 - 2012
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2006 - 2009
Stony Brook University Health Sciences Center School of MedicineClass of 2006

PubMed

"Off-Label" Use of Checkpoint Inhibitors in Patients With Negative or Unknown PD-L1 Status in Advanced Head and Neck Cancer.
Margaret Stalker, Kewen Qu, Roger B Cohen, Ronac Mamtani, Wei-Ting Hwang
Journal of the National Comprehensive Cancer Network. 2025-02-11
Evolving racial/ethnic disparities in AML survival in the novel therapy era.
Xin Wang, Phyllis A Gimotty, Andrew H Matthews, Ronac Mamtani, Selina M Luger
Blood Advances. 2025-02-11
Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations.
Xavier Orcutt, Kan Chen, Ronac Mamtani, Qi Long, Ravi B Parikh
Nature Medicine. 2025-02-01

Journal Articles

Cisplatin Versus Cetuximab with Definitive Concurrent Radiotherapy for Head and Neck Squamous Cell Carcinoma: An Analysis of Veterans Health Affairs Data
Ravi Vinnakota, Keith Sigel, Joshua M Bauml, Roger B Cohen, Nevena Damjanov, Corey J Langer, Ronac Mamtani, Charu Aggarwal, Christina Knepley, Juan Wisnivesky, Cancer

A New Look at the International Duration Evaluation of Adjuvant Therapy (IDEA) Classification—Defining Novel Predictive and Prognostic Markers in Stage III Colon CancerMay 2018
A New Look at the International Duration Evaluation of Adjuvant Therapy (IDEA) Classification—Defining Novel Predictive and Prognostic Markers in Stage III Colon CancerMay 2018
A New Look at the International Duration Evaluation of Adjuvant Therapy (IDEA) Classification—Defining Novel Predictive and Prognostic Markers in Stage III Colon CancerMay 2018

Can Text Messages Bypass in-Person Immunotherapy Check-Ins?: Penn MedicineFebruary 26th, 2025
Digital Triage Tool Significantly Reduces Cancer Treatment TimeFebruary 20th, 2025
Text Message Tool Addresses “Time Toxicity” for Cancer PatientsFebruary 19th, 2025
Join now to see all